160 related articles for article (PubMed ID: 38564841)
1. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
Gold S; Shilatifard A
Curr Opin Genet Dev; 2024 Jun; 86():102181. PubMed ID: 38564841
[TBL] [Abstract][Full Text] [Related]
2. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
4. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
5. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
6. Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation.
Zheng B; Gold S; Iwanaszko M; Howard BC; Wang L; Shilatifard A
Mol Cell; 2023 Aug; 83(16):2896-2910.e4. PubMed ID: 37442129
[TBL] [Abstract][Full Text] [Related]
7. Brd4's Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1.
Wu T; Kamikawa YF; Donohoe ME
Cell Rep; 2018 Nov; 25(7):1756-1771. PubMed ID: 30428346
[TBL] [Abstract][Full Text] [Related]
8. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain inhibitors and therapeutic applications.
Gajjela BK; Zhou MM
Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
[TBL] [Abstract][Full Text] [Related]
10. SWI/SNF-dependent chromatin remodeling of RNR3 requires TAF(II)s and the general transcription machinery.
Sharma VM; Li B; Reese JC
Genes Dev; 2003 Feb; 17(4):502-15. PubMed ID: 12600943
[TBL] [Abstract][Full Text] [Related]
11. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
12. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
13. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
14. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.
Borck PC; Guo LW; Plutzky J
Circ Res; 2020 Apr; 126(9):1190-1208. PubMed ID: 32324495
[TBL] [Abstract][Full Text] [Related]
15. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.
Crawford TD; Tsui V; Flynn EM; Wang S; Taylor AM; Côté A; Audia JE; Beresini MH; Burdick DJ; Cummings R; Dakin LA; Duplessis M; Good AC; Hewitt MC; Huang HR; Jayaram H; Kiefer JR; Jiang Y; Murray J; Nasveschuk CG; Pardo E; Poy F; Romero FA; Tang Y; Wang J; Xu Z; Zawadzke LE; Zhu X; Albrecht BK; Magnuson SR; Bellon S; Cochran AG
J Med Chem; 2016 Jun; 59(11):5391-402. PubMed ID: 27219867
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
White ME; Fenger JM; Carson WE
Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
[TBL] [Abstract][Full Text] [Related]
17. The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains.
Weissman JD; Singh AK; Devaiah BN; Schuck P; LaRue RC; Singer DS
J Biol Chem; 2021 Nov; 297(5):101326. PubMed ID: 34688663
[TBL] [Abstract][Full Text] [Related]
18. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
20. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
